Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors

Video

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

“As of August, we have completed dose levels 1 and 2, in the escalation component of our phase 1 trial. We’ve seen a very pleasant surprise, a partial response in a patient who has stage 4b gastric cancer at the second dose level, which is still a very low dose level. This patient has metastatic disease, and essentially had passed 2 prior treatment lines, including HER2-targeted therapies.”

TAC01-HER2 (Triumvira Immunologics), a HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, was well-tolerated and demonstrated early signs of clinical activity, including a partial response in a patient with stage 4b gastric cancer and a 75% disease control rate in cohort 2.

These data, from the phase 1/2 TACTIC-2 study, were presented at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France, by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute.

CGTLive spoke with Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, and senior author of the poster to learn more about the study and its recent updates. He discussed the trial’s progress so far and the cases of stable disease and partial response. The trial will be enrolling in its phase 2 portion in the beginning of 2023.

Click here to read more coverage of ESMO Congress 2022.

REFERENCE
Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP
Recent Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.